All Title Author
Keywords Abstract

Elevated Plasma Levels but Decreased Platelet-Associated Expression of LIGHT in Patients with Acute Atherothrombotic Stroke

DOI: 10.4236/wjns.2014.44042, PP. 385-393

Keywords: LIGHT, Ischemic Atherosclerotic Stroke, Atherogenesis, Peripheral Blood

Full-Text   Cite this paper   Add to My Lib


Background: As a member of the tumor necrosis factor superfamily (TNFSF), LIGHT (TNFSF14) is expressed by a variety of immune cells and exists in membrane-bound and soluble forms. Recently, LIGHT was found to be associated with platelets and released upon activation. Activation of endothelia cells by recombinant LIGHT protein results in pro-inflammatory and pro-thrombotic changes. Several studies have reported increased plasma levels of LIGHT in patients with stroke and cardiovascular diseases. However, the form-associated roles of LIGHT in ischemic atherosclerotic stroke remain unclear. Mater?als and Methods: In this study, the platelet LIGHT expression and soluble LIGHT protein were analyzed by flow cytometry and enzyme-linked immunosorbent assay (ELISA) in peripheral blood of patients with acute ischemic atherosclerotic stroke, asymptomatic carotid stenosis (ACS) and normal controls. RESULTS: During the initial 24 h after onset, the stroke patients had decreased LIGHT expression on their platelets (5.9% ± 4.9%) and increased plasma LIGHT levels (36.1 ± 21.0 pg/ml) as compared with normal controls (9.5% ± 3.0%, p < 0.05; 20.4 ± 13.4 pg/ml, p < 0.05). Moreover, the platelet LIGHT expression correlated with total plaque area in the stroke patients (r = 0.4572, p = 0.0247). Conclus?ons: The dysregulated LIGHT expression reflects a persistent chronic inflammatory


[1]  Elkind, M.S. (2006) Inflammation, Atherosclerosis and Stroke. Neurologist, 12, 140-148.
[2]  Weber, C. and Noels, H. (2011) Atherosclerosis: Current Pathogenesis and Therapeutic Options. Nature Medicine, 17, 1410-1422.
[3]  Libby, P. (2002) Inflammation in Atherosclerosis. Nature, 420, 868-874.
[4]  Buch, M.H., Prendergast, B.D. and Storey, R.F. (2010) Antiplatelet Therapy and Vascular Disease, an Update. Therapeutic Advances in Cardiovascular Disease, 4, 249-275.
[5]  Gerdes, N. and Zirlik, A. (2011) Co-Stimulatory Molecules in and beyond Co-Stimulation-Tipping the Balance in Atherosclerosis? Thrombosis and Haemostasis, 106, 804-813.
[6]  Hassan, G.S., Merhi, Y. and Mourad, W. (2012) CD40 Ligand: A Neo-Inflammatory Molecule in Vascular Diseases. Immunobiology, 217, 521-532.
[7]  Young, J.L., Libby, P. and Schonbeck, U. (2002) Cytokines in the Pathogenesis of Atherosclerosis. Thrombosis and Haemostasis, 88, 554-567.
[8]  McKellar, G.E., McCarey, D.W., Sattar, N. and McInnes, I.B. (2009) Role for TNF in Atherosclerosis? Lessons from Autoimmune Disease. Nature Reviews Cardiology, 6, 410-417.
[9]  Lee, W.H., Kim, S.H., Lee, Y., Lee, B.B., Kwon, B. and Park, J.E. (2001) Tumor Necrosis Factor Receptor Superfamily 14 Is Involved in Atherogenesis by Inducing Proinflammatory Cytokines and Matrix Metalloproteinases. Arteriosclerosis, Thrombosis, and Vascular Biology, 21, 2004-2010.
[10]  Otterdal, K., Smith, C., Oie, E., Pedersen, T.M., Yndestad, A., Stang, E., Endresen, K., Solum, N.O., Aukrust, P. and Damas, J.K. (2006) Platelet-Derived LIGHT Induces Inflammatory Responses in Endothelial Cells and Monocytes. Blood, 108, 928-935.
[11]  Kim, W.J., Kang, Y.J., Suk, K., Park, J.E., Kwon, B.S. and Lee, W.H. (2008) Comparative Analysis of the Expression Patterns of Various TNFSF/TNFRSF in Atherosclerotic Plaques. Immunological Investigations, 37, 359-373.
[12]  Chang, Y.H., Hsieh, S.L., Chao, Y., Chou, Y.C. and Lin, W.W. (2005) Proinflammatory Effects of LIGHT through HVEM and LTβR Interactions in Cultured Human Umbilical Vein Endothelial Cells. Journal of Biomedical Science, 12, 363-375.
[13]  Scholz, H., Sandberg, W., Damas, J.K., Smith, C., Andreassen, A.K., Gullestad, L., Froland, S.S., Yndestad, A., Aukrust, P. and Halvorsen, B. (2005) Enhanced Plasma Levels of LIGHT in Unstable Angina: Possible Pathogenic Role in Foam Cell Formation and Thrombosis. Circulation, 112, 2121-2129.
[14]  Celik, S., Langer, H., Stellos, K., May, A.E., Shankar, V., Kurz, K., Katus, H.A., Gawaz, M.P. and Dengler, T.J. (2007) Platelet-Associated LIGHT (TNFSF14) Mediates Adhesion of Platelets to Human Vascular Endothelium. Thrombosis and Haemostasis, 98, 798-805.
[15]  Liu, G.Z., Fang, L.B., Hjelmstrom, P. and Gao, X.G. (2008) Enhanced Plasma Levels of LIGHT in Patients with Acute Atherothrombotic Stroke. Acta Neurologica Scandinavica, 118, 256-259.
[16]  Adams Jr., H.P., Bendixen, B.H., Kappelle, L.J., Biller, J., Love, B.B., Gordon, D.L. and Marsh, E.E. (1993) Classification of Subtype of Acute Ischemic Stroke. Definitions for Use in a Multicenter Clinical Trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke, 24, 35-41.
[17]  Spence, J.D., Eliasziw, M., DiCicco, M., Hackam, D.G., Galil, R. and Lohmann, T. (2002) Carotid Plaque Area: A Tool for Targeting and Evaluating Vascular Preventive Therapy. Stroke, 33, 2916-2922.
[18]  Spence, J.D. (2006) Technology Insight: Ultrasound Measurement of Carotid Plaque—Patient Management, Genetic Research, and Therapy Evaluation. Nature Clinical Practice Neurology, 2, 611-619.
[19]  Cohavy, O., Zhou, J., Ware, C.F. and Targan, S.R. (2005) LIGHT Is Constitutively Expressed on T and NK Cells in the Human Gut and Can Be Induced by CD2-Mediated Signaling. The Journal of Immunology, 174, 646-653.
[20]  Schneider, K., Potter, K.G. and Ware, C.F. (2004) Lymphotoxin and LIGHT Signaling Pathways and Target Genes. Immunological Reviews, 202, 49-66.
[21]  del Rio, M.L., Lucas, C.L., Buhler, L., Rayat, G. and Rodriguez-Barbosa, J.I. (2010) HVEM/LIGHT/BTLA/CD160 Cosignaling Pathways as Targets for Immune Regulation. Journal of Leukocyte Biology, 87, 223-235.
[22]  Celik, S., Shankar, V., Richter, A., Hippe, H.J., Akhavanpoor M., Bea, F., Erbel, C., Urban, S., Blank, N., Wambsganss, N., Katus, H.A. and Dengler, T.J. (2009) Proinflammatory and Prothrombotic Effects on Human Vascular Endothelial Cells of Immune-Cell-Derived LIGHT. European Journal of Medical Research, 14, 147-156.
[23]  Garlichs, C.D., Kozina, S., Fateh-Moghadam, S., Handschu, R., Tomandl, B., Stumpf, C., Eskafi, S., Raaz, D., Schmeisser, A., Yilmaz, A., Ludwig, J., Neundorfer, B. and Daniel, W.G. (2003) Upregulation of CD40-CD40 Ligand (CD154) in Patients with Acute Cerebral Ischemia. Stroke, 34, 1412-1418.
[24]  Garrido, V.T., Proenca-Ferreira, R., Dominical, V.M., Traina, F., Bezerra, M.A., de Mello, M.R., Colella, M.P, Araújo, A.S., Saad, S.T., Costa, F.F. and Conran, N. (2012) Elevated Plasma Levels and Platelet-Associated Expression of the Pro-Thrombotic and Pro-Inflammatory Protein, TNFSF14 (LIGHT), in Sickle Cell Disease. British Journal of Haematology, 158, 788-797.


comments powered by Disqus